{"id":"https://openalex.org/W2001454508","doi":"https://doi.org/10.1212/wnl.78.1_meetingabstracts.p04.194","title":"Responders to ELND005 (Scyllo-Inositol) Demonstrate Clinical and Biomarker Characteristics Consistent with Mild Alzheimer's Disease (AD): Data from a 78-Week Phase 2 Study in Mild to Moderate (M/M) AD (P04.194)","display_name":"Responders to ELND005 (Scyllo-Inositol) Demonstrate Clinical and Biomarker Characteristics Consistent with Mild Alzheimer's Disease (AD): Data from a 78-Week Phase 2 Study in Mild to Moderate (M/M) AD (P04.194)","publication_year":2012,"publication_date":"2012-04-22","ids":{"openalex":"https://openalex.org/W2001454508","doi":"https://doi.org/10.1212/wnl.78.1_meetingabstracts.p04.194","mag":"2001454508"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.78.1_meetingabstracts.p04.194","doi":"https://doi.org/10.1212/wnl.78.1_meetingabstracts.p04.194","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.78.1_meetingabstracts.p04.194","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5033585095","display_name":"Anton P. Porsteinsson","orcid":"https://orcid.org/0000-0002-0166-1738","observed_orcids":["https://orcid.org/0000-0002-0166-1738"]},"institutions":[{"id":"https://openalex.org/I28792581","display_name":"University of Rochester Medicine","ror":"https://ror.org/00trqv719","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I28792581","https://openalex.org/I5388228"]},{"id":"https://openalex.org/I5388228","display_name":"University of Rochester","ror":"https://ror.org/022kthw22","country_code":"US","type":"education","lineage":["https://openalex.org/I5388228"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Porsteinsson","raw_affiliation_strings":["Psychiatry, University of Rochester, Rochester, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Psychiatry, University of Rochester, Rochester, NY","institution_ids":["https://openalex.org/I28792581","https://openalex.org/I5388228"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001795846","display_name":"Reisa Anne Sperling","orcid":"https://orcid.org/0000-0003-1535-6133","observed_orcids":["https://orcid.org/0000-0003-1535-6133"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Sperling","raw_affiliation_strings":["Neurology Harvard University, Brigham and Women's Hospital Boston MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurology Harvard University, Brigham and Women's Hospital Boston MA","institution_ids":["https://openalex.org/I1283280774","https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002183686","display_name":"Stephen Salloway","orcid":"https://orcid.org/0000-0002-2631-0942","observed_orcids":["https://orcid.org/0000-0002-2631-0942"]},"institutions":[{"id":"https://openalex.org/I27804330","display_name":"Brown University","ror":"https://ror.org/05gq02987","country_code":"US","type":"education","lineage":["https://openalex.org/I27804330"]},{"id":"https://openalex.org/I2802060973","display_name":"Butler Hospital","ror":"https://ror.org/00z9zsj19","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2802060973"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Salloway","raw_affiliation_strings":["Neurology Butler Hospital and Brown University Providence RI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurology Butler Hospital and Brown University Providence RI","institution_ids":["https://openalex.org/I27804330","https://openalex.org/I2802060973"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076954519","display_name":"Gerald Crans","orcid":"https://orcid.org/0000-0002-5558-7879","observed_orcids":["https://orcid.org/0000-0002-5558-7879"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. Crans","raw_affiliation_strings":["Elan Pharmaceuticals South San Francisco CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Elan Pharmaceuticals South San Francisco CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111620035","display_name":"C. Hernandez","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Hernandez","raw_affiliation_strings":["Elan Pharmaceuticals South San Francisco CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Elan Pharmaceuticals South San Francisco CA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5113687686","display_name":"Susan R. Abushakra","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267435","display_name":"Elan Pharmaceuticals, Inc. (Ireland)","ror":"https://ror.org/02s1xv184","country_code":"IE","type":"company","lineage":["https://openalex.org/I4405267435"]}],"countries":["IE"],"is_corresponding":false,"raw_author_name":"S. Abushakra","raw_affiliation_strings":["Elan Pharmaceuticals San Jose CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Elan Pharmaceuticals San Jose CA","institution_ids":["https://openalex.org/I4405267435"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":7,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"78","issue":"Meeting Abstracts 1","first_page":"P04.194","last_page":"P04.194"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.9359999895095825,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.9359999895095825,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10009","display_name":"Dementia and Cognitive Impairment Research","score":0.06289999932050705,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12023","display_name":"Cholinesterase and Neurodegenerative Diseases","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/scyllo-inositol","display_name":"scyllo-inositol","score":0.9800000190734863},{"id":"https://openalex.org/keywords/mild-alzheimer-s-disease","display_name":"mild Alzheimer's disease","score":0.8930000066757202},{"id":"https://openalex.org/keywords/disease-modifying-therapy","display_name":"disease-modifying therapy","score":0.6549999713897705},{"id":"https://openalex.org/keywords/csf-tau","display_name":"CSF tau","score":0.5220000147819519},{"id":"https://openalex.org/keywords/brain-atrophy","display_name":"brain atrophy","score":0.6980000138282776},{"id":"https://openalex.org/keywords/ventricular-dilation","display_name":"ventriculomegaly","score":0.9549999833106995},{"id":"https://openalex.org/keywords/mri-biomarkers","display_name":"MRI biomarkers","score":0.5180000066757202},{"id":"https://openalex.org/keywords/cognitive-decline","display_name":"cognitive decline","score":0.47200000286102295},{"id":"https://openalex.org/keywords/predictors-of-treatment-response","display_name":"predictors of treatment response","score":0.46799999475479126},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.5659999847412109}],"concepts":[{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.6821959018707275},{"id":"https://openalex.org/C502032728","wikidata":"https://www.wikidata.org/wiki/Q11081","display_name":"Alzheimer's disease","level":3,"score":0.5501396059989929},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.4938217103481293},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4921233057975769},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.473772794008255},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.43074941635131836},{"id":"https://openalex.org/C2777427919","wikidata":"https://www.wikidata.org/wiki/Q407997","display_name":"Inositol","level":3,"score":0.4255639612674713},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.14937779307365417},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.12119588255882263},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.09209027886390686}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.78.1_meetingabstracts.p04.194","doi":"https://doi.org/10.1212/wnl.78.1_meetingabstracts.p04.194","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.78.1_meetingabstracts.p04.194","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2016573373","https://openalex.org/W1972917675","https://openalex.org/W2108851969","https://openalex.org/W2119197968","https://openalex.org/W1979100063","https://openalex.org/W2113658003","https://openalex.org/W2127642100","https://openalex.org/W2896271121","https://openalex.org/W2608559677","https://openalex.org/W2015329082"],"abstract_inverted_index":{"Objective:":[0],"To":[2],"describe":[3],"the":[4,208,220,230,237],"clinical":[5,202],"and":[6,10,54,102,178,189,201,234,271,288,304,318,342,373,387,392],"biomarker":[7],"characteristics":[8],"(v-MRI":[9],"CSF)":[11],"of":[12,121,198,223],"patients":[13,44],"who":[14,163],"demonstrated":[15],"cognitive":[16],"benefit":[17,222],"on":[18,115,134],"ELND005,":[19],"a":[20,33,123,307],"candidate":[21],"disease":[22,173],"modifying":[23],"agent.":[24],"Background":[27],"Post-hoc":[29],"analyses":[30,112],"were":[31,62,107,113,205],"from":[32,105,279,315,351],"Phase":[34],"2,":[35],"placebo-controlled,":[36],"78":[37,98,169,195],"week":[38],"study":[39,214],"in":[40,93],"353":[41],"M/M":[42],"AD":[43,232],"(MMSE":[45],"16-26),":[46],"which":[47],"included":[48],"3":[49,95],"active":[50],"arms":[51],"(250,":[52],"1000":[53],"2000mg":[55],"all":[56,94],"BID).":[57],"The":[58],"2":[59],"highest":[60],"doses":[61,96],"discontinued":[63],"due":[64],"to":[65,143],"safety":[66],"findings":[67],"(Salloway":[68],"et":[69],"al.":[70],"Neurology":[71],"2011).":[72],"Design/Methods:":[75],"Clinical":[77,140,182],"response":[78,116],"was":[79],"defined":[80,118],"as":[81,119,306,406,420],"improved":[82,164],"or":[83,165],"stable":[84,167],"Neuropsychological":[85],"Test":[86],"Battery":[87],"scores":[88],"(NTB,":[89],"co-primary":[90],"outcome)":[91],"assessed":[92],"at":[97,128,168,174,213,229],"weeks.":[99,196],"Baseline":[100],"parameters":[101],"percent":[103],"changes":[104,204],"baseline":[106,150],"compared":[108,142],"using":[109],"t-tests.":[110],"Correlation":[111],"performed":[114],"rate,":[117],"number":[120],"times":[122],"patient9s":[124],"NTB":[125],"remained":[126,166],"\u22650":[127],"any":[129],"visit":[130],"divided":[131],"by":[132,176,207],"time":[133],"study.":[135],"Results:":[138],"responders":[141,183],"non-responders":[144,193],"(n=":[145],"39/109),":[146],"had":[147,171],"significantly":[148,185],"higher":[149],"MMSE":[151,177],"(mean":[152],"23.3":[153],"versus":[154],"20.6,":[155],"p":[156],"Conclusions:":[160],"Patients":[162],"weeks":[170],"mild":[172],"baseline,":[175],"CSF":[179,199,210],"tau":[180],"pararmeters.":[181],"developed":[184],"less":[186],"brain":[187],"atrophy":[188],"ventricular":[190],"enlargement":[191],"than":[192],"over":[194],"Correlations":[197],"biomarkers":[200],"outcome":[203],"limited":[206],"small":[209],"sample":[211],"size":[212],"endpoint":[215],"(N=34).":[216],"These":[217],"data":[218],"support":[219,278,314,350],"potential":[221],"ELND005":[224],"when":[225],"treatment":[226],"is":[227],"initiated":[228],"Mild":[231],"stage,":[233],"help":[235],"define":[236],"population":[238],"for":[239,261,296,326,382,401,415],"future":[240],"studies.":[241],"Supported":[243],"by:":[244],"Elan":[245,305,329,366,385,404],"Pharmaceuticals,":[246,332,365],"South":[247],"San":[248],"Francisco,":[249],"CA.":[250],"Disclosure:":[253],"Dr.":[255,290,309,320,345,376,395,409],"Porsteinsson":[256,274],"has":[257,275,292,311,322,347,378,397,411],"received":[258,276,293,312,323,348,379,398],"personal":[259,294,324,380,399,413],"compensation":[260,295,325,381,400,414],"activities":[262,297,327,383,402,416],"with":[263,298,328,384,403,417],"Medivation,":[264,285,361],"Elan,":[265,282],"Janssen":[266,283,359],"Immunotherapy,":[267,284],"Pfizer,":[268,286],"Transition":[269],"Therapeutics,":[270],"Forest":[272,356],"LaboratoriesDr":[273],"research":[277,313,349],"BMS,":[280],"Baxter,":[281],"Toyama,":[287],"Wyeth.":[289],"Sperling":[291,310],"Pfizer":[299,334,354],"Inc,":[300,335,355],"Bristol-Myers":[301,316,338,370],"Squibb,":[302,339,371],"Janssen,":[303],"consultant.":[308],"Squibb":[317],"Elan.":[319],"Salloway":[321,346],"Corporation,":[330,367],"Sanofi-Aventis":[331],"Inc.,":[333,337,353,358,363],"Eisai":[336,352],"Novartis,":[340],"Forest,":[341],"Athena":[343],"Diagnostics.":[344],"Laboratories,":[357],"Pharmaceutica,":[360],"GlaxoSmithKline,":[362],"Myriad":[364],"Neurochem,":[368],"Wyeth,":[369],"Voyager,":[372],"Cephalon,":[374],"Inc.":[375],"Crans":[377],"Pharmaceuticals":[386,405],"JANSSEN":[388],"Alzheimer":[389],"Immunotherapy":[390],"Research":[391],"Development,":[393],"LLC.":[394],"Hernandez":[396],"an":[407,421],"employee.":[408,422],"Abu-Shakra":[410],"receievd":[412],"Allergan,":[418],"Inc":[419]},"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}